Recent studies show a steady increase in the use of atypical antipsychotics among children, despite concerns that these drugs might cause weight gain and metabolic disorders. Meanwhile, the FDA approved the use of risperidone in children suffering from schizophrenia. The agency is scheduled in June to review AstraZeneca's application to market Seroquel to children with schizophrenia or bipolar disorder.

Related Summaries